Orphazyme To Cut Two-Third Workforce Under Restructuring; Reaffirms FY21 Outlook

Loading...
Loading...

 


  • Orphazyme A/S ORPH plans an approximate two-thirds reduction in its global workforce due to a restructuring, aiming to advance its corporate strategy and the development of arimoclomol for Niemann-Pick disease type C (NPC).

  • The company further said it remains committed to pursuing regulatory approval in Europe and assessing a path forward for arimoclomol in the U.S. after being hit by a Complete Response Letter from the FDA last week.

  • NPC is a rare, genetic, progressively debilitating, and often fatal neurovisceral disease.

  • Regarding its trading, Orphazyme said its financial outlook remains unchanged for 2021. 

  • With the planned restructuring and resulting cost savings, the company intends to free resources.

  • Concurrently, the company announced 24-month interim results of an open-label extension trial for arimoclomol in NPC.

  • The data were shared at the Parseghian Scientific Conference for Niemann-Pick disease type C Research.

  • A slowing of progression from baseline was observed through 36 months in participants who received arimoclomol from the start of the double-blind phase (mean change, 3.5 points). 

  • The effect was consistent across pre-specified subgroups, including those treated with miglustat among participants more than four years of age. 

  • Also, slowing of progression through 24 months was observed in those participants who initiated arimoclomol treatment upon entering the open-label period (mean change, 0.9 points).

  • Price Action: ORPH shares are down 1.78% at $7.71 during the premarket session on the last check Monday.


  •  

 

 

 

Loading...
Loading...
Posted In: BiotechEarningsNewsGuidanceHealth CareFDAGeneralBriefsNiemann-Pick disease type C
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...